GlassScriptPhysician profile
Josef Lobel
NPI 1295769230
$3,616.76
in general payments reported to CMS, 2019-2025
21 companies · $689 in 2025
The $689 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $43.57 · 2021: $179 · 2022: $554 · 2023: $558 · 2024: $987 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,229 · Travel and Lodging: $5.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,229.46 |
| Travel and Lodging | $5.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $626.28 | 2019-2025 | Otezla, Prolia, Evenity |
| Otsuka America Pharmaceutical, INC. | $297.45 | 2024 | Rexulti |
| Lilly USA, LLC | $271.89 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $266.35 | 2023-2025 | Wegovy, Saxenda |
| Regeneron Healthcare Solutions, INC. | $241.81 | 2022-2023 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $209.96 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $209.39 | 2024-2025 | Caplyta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $204.94 | 2024-2025 | Lifevest |
| Edwards Lifesciences Corporation | $203.58 | 2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amarin Pharma, INC. | $189.43 | 2019-2021 | |
| Exact Sciences Corporation | $150.79 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $139.63 | 2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Neurocrine Biosciences, INC. | $136.20 | 2022 | |
| Abbott Laboratories | $128.09 | 2019 | |
| Novartis Pharmaceuticals Corporation | $81.28 | 2022-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $71.06 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $54.78 | 2021-2023 | Steglatro, Belsomra |
| Phathom Pharmaceuticals, INC. | $39.47 | 2024 | Voquezna |
| Kvk-Tech, INC. | $37.08 | 2019 | |
| Astellas Pharma US INC | $36.11 | 2019-2022 | |
| Allergan, INC. | $21.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josef Lobel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.